ResMed: Digital Health Drives Q2 Growth
(NYSE:RMD), a leader in sleep apnea and respiratory care solutions, reported strong fiscal 2025 second-quarter earnings on Thursday, Jan. 30. The medical device company outperformed analyst consensus forecasts with adjusted EPS of $2.43 topping the $2.32 estimate and revenue of $1.282 billion beating the expected $1.266 billion.
The great quarter was driven by high demand for sleep-related products and growth in digital health solutions.
Source: ResMed. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year.
Source Fool.com
Resmed Inc. Aktie
195,00 €
-0,41 %
Deutliche Buy-Präferenz bei Resmed Inc. ohne Sell-Einschätzungen.
Ein Kursziel von 256 € für Resmed Inc. signalisiert eine potenzielle Steigerung von über 20% gegenüber dem aktuellen Kurs von 195.0 €.
